Hans Moebius, MD, PhD, ECPM, FAAN – is an internationally recognized expert in neuropsychiatry R&D and regulatory strategy with over 30 years of leading R&D positions at Ciba-Geigy, Novartis, Merz, INC Research, TauRx (Singapore), FORUM (USA), CHASE (USA), and Rodin (USA). During his career, Dr. Moebius has been leading or was closely involved in extensive R&D projects leading to six new CNS therapies in Alzheimer’s Disease (memantine; licensed out to Forest Labs NYC, Lundbeck/Copenhagen, Daiichi/Tokyo), hepatic encephalopathy (LOLA), Lennox-Gastaut-Syndrome (rufinamide), Complex Partial Seizures (oxcarbazepine), dystonia / blepharospasm / post-stroke spasticity (botulium toxin A free of complexing proteins by EMA, FDA; licensed out to Allergan), and ADHD (Ritalin® SR). Dr. Moebius has received a number of professional distinctions, including heading up the R&D team that won the German Industry Innovation Award for the international development of memantine in late-stage Alzheimer’s disease (2002). He is the Fellow of American Academy of Neurology since 2016 and was appointed Honorary Research Fellow by the University of Aberdeen in 2010. Dr. Moebius is a long-term member of the International Society for CNS Clinical Trail Methodology, the American Academy of Neurology and the International Schizophrenia Research Society and a founding member of the American Society for Experimental Neurotherapeutics and the Swiss Association of Pharmaceutical Physicians. Dr. Moebius earned a bachelor of science degree in chemistry from the University of Kaiserslautern, Germany, and his PhD degree in experimental pharmacology from the University of Heidelberg. He is a board certified psychiatrist and neurologist who completed his medical studies at the Universities of Bordeaux/France, (West) Berlin, Heidelberg and Frankfurt/Germany, where he has been lecturing during his research tenure at the Max-Planck-Institute for Brain Research. He also holds the European Degree in Pharmaceutical Medicine (ECPM) by the EUCOR Universities Basel/Switzerland, Freiburg/Germany and Strasbourg/France.